Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

Bibliography

• Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother 2015;16:43-62
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101
   PubMed Web of Science ®Google Scholar
• Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33:1609-29
   PubMed Web of Science ®Google Scholar
• Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:223-42
   PubMed Web of Science ®Google Scholar
• Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2014;74:587-610
   PubMed Web of Science ®Google Scholar
• Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf 2013;12:103-9
   PubMed Web of Science ®Google Scholar
• Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother 2013;47:1532-9
   PubMed Web of Science ®Google Scholar
• Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
   PubMed Web of Science ®Google Scholar
• Lajara R. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin Pharmacother 2012;13:2663-71
   PubMed Web of Science ®Google Scholar
• McKeage K. Linagliptin: an update of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:1927-46
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf 2014;5:138-46
   PubMedGoogle Scholar
• Ceriello A, Sportiello L, Rafaniello C, et al. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf 2014;13(Suppl 1):S57-68
   PubMed Web of Science ®Google Scholar
• Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092-5
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
   PubMed Web of Science ®Google Scholar
• Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012;14:1061-72
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of SGLT2 inhibitors for the treatment of type 2 diabetes. Drugs 2015;75(1):33-59
   PubMed Web of Science ®Google Scholar
• Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008;51:141-7
   PubMed Web of Science ®Google Scholar
• Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009;54:516-23
   PubMed Web of Science ®Google Scholar
• Byrd JS, Minor DS, Elsayed R, et al. DPP-4 inhibitors and angioedema: a cause for concern? Ann Allergy Asthma Immunol 2011;106:436-8
   PubMed Web of Science ®Google Scholar
• Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabet Med 2013;30:e149-50
   PubMed Web of Science ®Google Scholar
• Bene J, Jacobsoone A, Coupe P, et al. Bullous pemphigoid induced by vildagliptin: a report of three cases. Fundam Clin Pharmacol 2014;29:112-4
   PubMed Web of Science ®Google Scholar
• Attaway A, Mersfelder TL, Vaishnav S, et al. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatoll Case Rep 2014;8:24-8
   PubMedGoogle Scholar
• Skandalis K, Spirova M, Gaitanis G, et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012;26:249-53
   PubMed Web of Science ®Google Scholar
• Tarapues M, Cereza G, Figueras A. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf 2013;22:1115-18
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011;34:2474-6
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
   PubMed Web of Science ®Google Scholar
• Engel SS, Round E, Golm GT, et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013;4:119-45
   PubMed Web of Science ®Google Scholar
• Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:f2267
   PubMed Web of Science ®Google Scholar
• Forst T, Bramlage P. Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opin Pharmacother 2014;15:1299-313
   PubMed Web of Science ®Google Scholar
• Cai L, Cai Y, Lu ZJ, et al. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther 2012;37:386-98
   PubMed Web of Science ®Google Scholar
• Bluher M, Kurz I, Dannenmaier S, et al. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012;3:161-9
   PubMedGoogle Scholar
• Goke R, Bader G, Dworak M. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. Diabetes 2014;5:183-91
   Google Scholar
• Simon D, Detournay B, Eschwege E, et al. Use of vildagliptin in management of type 2 diabetes: effectiveness, treatment persistence and safety from the 2-year real-life VILDA study. Diabetes Ther 2014;5:207-24
   Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Davidson JA. Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. J Manag Care Pharm 2014;20:120-9
   PubMed Web of Science ®Google Scholar
• Hirshberg B, Parker A, Edelberg H, et al. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2014;30:556-69
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Gross JL, Aguilar Salinas C, et al. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with type 2 diabetes. Diabet Med 2013;30:1472-6
   PubMed Web of Science ®Google Scholar
• Lo Re V 3rd, Haynes K, Ming EE, et al. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 2012;21:1202-15
   PubMed Web of Science ®Google Scholar
• Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord 2013;13:9
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014;15:851-63
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Alogliptin: concern about hepatotoxicity? Clin Pharmacokinet 2014;53:1057-9
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:470-8
   PubMed Web of Science ®Google Scholar
• Lehrke M, Marx N, Patel S, et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther 2014;36:1130-46
   PubMed Web of Science ®Google Scholar
• Barnett AH. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. Expert Opin Drug Saf 2015;14:149-59
   PubMed Web of Science ®Google Scholar
• Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-25
   PubMed Web of Science ®Google Scholar
• Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013;36:2126-32
   PubMed Web of Science ®Google Scholar
• Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf 2013;12:545-57
   PubMed Web of Science ®Google Scholar
• Suarez EA, Koro CE, Christian JB, et al. Incretin-mimetic therapies and pancreatic disease: a review of observational data. Curr Med Res Opin 2014;30:2471-81
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013;62:3316-23
   PubMed Web of Science ®Google Scholar
• de Heer J, Goke B. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas? Expert Opin Drug Saf 2014;13:1469-81
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2013;50:569-77
   PubMed Web of Science ®Google Scholar
• Faillie JL, Babai S, Crepin S, et al. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the french pharmacovigilance database. Acta Diabetol 2014;51:491-7
   PubMed Web of Science ®Google Scholar
• Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64
   PubMed Web of Science ®Google Scholar
• Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin. Diabetes Care 2014;37:2435-41
   PubMed Web of Science ®Google Scholar
• Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014;57:1320-4
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:48-56
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Garg R, Hussey C, Ibrahim S. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabet Med 2010;27:485-6
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9
   PubMed Web of Science ®Google Scholar
• Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014;2:111-15
   PubMed Web of Science ®Google Scholar
• Faillie JL, Azoulay L, Patenaude V, et al. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014;348:g2780
   PubMed Web of Science ®Google Scholar
• Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug Saf 2014;37:521-8
   PubMed Web of Science ®Google Scholar
• Yabe D, Kuwata H, Kaneko M, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wang T, Wang F, Gou Z, et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies. Diabetes Obes Metab 2015;17:32-41
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014;370:794-7
   PubMed Web of Science ®Google Scholar
• Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-604
   PubMed Web of Science ®Google Scholar
• Bonner-Weir S, In’t Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab 2014;16:661-6
   PubMed Web of Science ®Google Scholar
• Gokhale M, Buse JB, Gray CL, et al. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab 2014;16:1247-56
   PubMed Web of Science ®Google Scholar
• Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 2014;40:176-85
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med 2013;125:7-20
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Dimmitt SB. Gliptins - do they increase cardiovascular risk or benefit? Expert Opin Drug Saf 2014;13:675-80
   PubMed Web of Science ®Google Scholar
• Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-20
   PubMed Web of Science ®Google Scholar
• Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013;12:3
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
   PubMed Web of Science ®Google Scholar
• Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012;11:6
   PubMed Web of Science ®Google Scholar
• Iqbal N, Parker A, Frederich R, et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014;13:33
   PubMed Web of Science ®Google Scholar
• White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:668-73
   PubMed Web of Science ®Google Scholar
• Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator carolina trial. Diab Vasc Dis Res 2013;10:289-301
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475-83
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hong J, Chi J, et al. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 2014;30:241-56
   PubMed Web of Science ®Google Scholar
• Kim SC, Glynn RJ, Liu J, et al. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol 2014;51:1015-23
   PubMed Web of Science ®Google Scholar
• Mogensen UM, Andersson C, Fosbol EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study. Diabetes Obes Metab 2014;16:1001-8
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-803
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of gliptins. Nature reviews Cardiology 2013;10:73-84
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation 2014;130:1579-88
   PubMed Web of Science ®Google Scholar
• Krum H, Skiba M, Wu S, et al. Heart failure and dipeptidyl peptidase-4 inhibitors. Eur J Heart Fail 2014;16:603-7
   PubMed Web of Science ®Google Scholar
• Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 2014;16:353
   PubMedGoogle Scholar
• Zannad F, Cannon C, Cushman W, et al. Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients (abstract). J Am Coll Cardiol 2014;63:A117
   Web of Science ®Google Scholar
• Evans M, McInnes G, Stumvoll M, et al. Assessment of heart failure risk with vildagliptin in diabetic patients: pooled analysis of safety data from approximately 17,000 patients. Diabetologia 2014;57(Suppl 1):S361
   Google Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-97
   PubMed Web of Science ®Google Scholar
• Clifton P. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? Clin Ther 2014;36:2072-9
   PubMed Web of Science ®Google Scholar
• Yu OH, Filion KB, Azoulay L, et al. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart failure 2014;2:573-82
   PubMed Web of Science ®Google Scholar
• Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-58
   PubMed Web of Science ®Google Scholar
• Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging 2014;31:203-14
   PubMed Web of Science ®Google Scholar
• Strain WD, Lukashevich V, Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013;382:409-16
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S. Experience with vildagliptin in patients >/=75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther 2013;4:257-67
   PubMed Web of Science ®Google Scholar
• Pratley RE, Rosenstock J, Pi Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-22
   PubMed Web of Science ®Google Scholar
• Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged >/= 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 2013;8:419-30
   PubMed Web of Science ®Google Scholar
• Iqbal N, Allen E, Ohman P. Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged >/= 65 years) with type 2 diabetes. Clin Interv Aging 2014;9:1479-87
   PubMed Web of Science ®Google Scholar
• Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1413-23
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Barnett AH, Patel S, et al. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged >/= 65 years. Diabetes Obes Metab 2014;16:1078-86
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013;15:906-14
   PubMed Web of Science ®Google Scholar
• Bron M, Wilson C, Fleck P. A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diabetes Ther 2014;5:521-34
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14
   PubMed Web of Science ®Google Scholar
• Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529-50
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 2015;54:1-21
   PubMed Web of Science ®Google Scholar
• Davis TM. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes Obes Metab 2014;16:891-9
   PubMed Web of Science ®Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013;36:1067-73
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013;61:579-87
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Shao Q, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947-54
   PubMed Web of Science ®Google Scholar
• Kothny W, Shao Q, Groop PH, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency. Diabetes Obes Metab 2012;14(11):1032-9
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Schweizer A, Foley JE, et al. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-8
   PubMedGoogle Scholar
• Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011;58:979-87
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-32
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-9
   PubMed Web of Science ®Google Scholar
• McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36:237-44
   PubMed Web of Science ®Google Scholar
• Groop PH, Del Prato S, Taskinen MR, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 2014;16:560-8
   PubMed Web of Science ®Google Scholar
• Fujii Y, Abe M, Higuchi T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother 2013;14:259-67
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Inagaki M, Shimizu T, et al. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study. Nephron Clin Pract 2013;123:46-51
   PubMed Web of Science ®Google Scholar
• Sakai Y, Suzuki A, Mugishima K, et al. Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. Intern Med 2014;53:195-203
   PubMed Web of Science ®Google Scholar
• Mikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med 2012;124:138-44
   PubMed Web of Science ®Google Scholar
• Ramirez G, Morrison AD, Bittle PA. Clinical practice considerations and review of the literature for the use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease. Endocr Pract 2013;19:1025-34
   PubMed Web of Science ®Google Scholar
• Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 2014;46:406-19
   PubMed Web of Science ®Google Scholar
• Cheng D, Fei Y, Liu Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. PLoS One 2014;9:e111543
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014;53:773-85
   PubMed Web of Science ®Google Scholar
• Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013;19:2298-306
   PubMed Web of Science ®Google Scholar
• Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63
   PubMedGoogle Scholar
• Scheen AJ, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet 2012;380:450-2
   PubMed Web of Science ®Google Scholar
• Gallwitz B, Rosenstock J, Patel S, et al. Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points over a 2-year trial. Diabetes Obes Metab 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Monami M, Dicembrini I, Kundisova L, et al. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab 2014;16:833-40
   PubMed Web of Science ®Google Scholar
• Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013;15:55-61
   PubMed Web of Science ®Google Scholar
• Gitt AK, Bramlage P, Binz C, et al. Prognostic implications of DPP-4 inhibitor vs sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry. Int J Clin Pract 2013;67:1005-14
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
   PubMed Web of Science ®Google Scholar